


Michael Cymbor, OD, FAAO
COPE 98001-TD

Retina Update



The slide features three images: a line graph showing a periodic waveform with peaks at approximately 20, 40, 60, and 80 on the x-axis; a fundus photograph showing a network of retinal vessels; and a larger fundus photograph showing a central optic disc and surrounding retinal vessels.

1

Disclosure Dr. Cymbor

- Key opinion leader and/or speaker for:
 - Visionix (Optovue)
 - Quidel
 - New World Medical
 - LKC Technologies
 - Allergan
 - Tarsus
 - Topcon
 - Thea

All financial relationships have been mitigated

2

Ways to reach out

mcybor@nittanyeye.com



MIKECYMBOR.COM

The slide includes icons for Facebook, LinkedIn, and YouTube.

3



Fred H. Carlin,
O.D. Community
Vision Foundation

- www.fhcvision.org

The image shows three men in medical scrubs standing outdoors, holding a large vision chart.


4

Case

- 46 Y/O W/F
- Type 2 Diabetes x 5 years, HTN x 5 years
 - Metformin
 - Last A1C 6.8
- No previous retinopathy
- BP 162/92 RAS
- LDL-C 160mg/dL
- Reports little to no exercise

5

Retinopathy?



The slide displays two side-by-side fundus photographs of the retina, showing the optic disc and retinal vessels.


6

Do you...

Tell her that she has no signs of retinopathy, keep doing what she's doing and see her in a year?

7

Or do you...



8

Or do you...

- 1**

Diagnose her with hypertensive and diabetic retinopathy/retinal ischemia
- 2**

Explain that her BP and A1C are too high and contact PCP
- 3**

Recommend that she be on cholesterol meds
- 4**

Recommend an exercise program
- 5**

Consider diabetic nutraceutical supplementation and electronic blood sugar monitoring

9

Interventional Management


Glaucoma

Diabetic Retinopathy?

10

In the Management of Diabetic Retinopathy

When is the right time to refer to retina?




11

Case


- 59 Y/O W/F
- Last year's exam – mild nonproliferative diabetic retinopathy OU
- Reports fluctuating blood sugars, last A1C 8.1
- BP 147/93 RAS
- Last LDL-C was 163
- Little to no exercise
- Vision seems different
- BCVA 20/20 OD and OS
- NS1




12



13




14



15



16




17

OD Coder


- **Fundus Photography 92250**
 - \$35.98
 - Written order and interpretation
 - Bilateral
 - Unilateral RT or LT with 52 modifier (reduced services)
 - Not a substitute for a dilated exam
 - “if the study is performed as a screening, it is not covered by medicare”
 - Mutually exclusive with OCT nerve/macula – 59 modifier
- **Now covered with E11.9**

Glare sensitivity H53.71
Retinal ischemia H35.82
Visual discomfort H53.143
Visual distortions of shape and size H53.15


18




19




20




21



22



23



24

Downgrade to moderate nonproliferative diabetic retinopathy

- 1 Discuss with PCP
- 2 Start walking program
- 3 Begin diabetic supplements
- 4 Discuss mediterranean diet
- 5 Recommend more aggressive HTN and cholesterol management

25

Case

- 46 Y/O H/M
- Exam 1 year ago with moderate nonproliferative diabetic retinopathy
- On metformin and glipizide
- Reports borderline high cholesterol at last PCP visit, BP today 152/93
- BCVA 20/20 OD and OS
- Mac OCT below 300 microns



26



27

OCT-A

28

ERG

| Right Eye | Left Eye |
|---|---|
| 100 Hz (20.00%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 100 Hz (20.00%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 30 Hz (7.50%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 30 Hz (7.50%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 15 Hz (3.75%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 15 Hz (3.75%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 7.5 Hz (1.88%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 7.5 Hz (1.88%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 3.75 Hz (0.94%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 3.75 Hz (0.94%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 1.88 Hz (0.47%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 1.88 Hz (0.47%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 0.94 Hz (0.23%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 0.94 Hz (0.23%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 0.47 Hz (0.12%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 0.47 Hz (0.12%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 0.23 Hz (0.06%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 0.23 Hz (0.06%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 0.12 Hz (0.03%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 0.12 Hz (0.03%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 0.06 Hz (0.01%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 0.06 Hz (0.01%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 0.03 Hz (0.00%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 0.03 Hz (0.00%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |
| 0.01 Hz (0.00%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) | 0.01 Hz (0.00%) 21.1 = 21.2 (1.03) 10.7 = 10.2 (0.95) |

29

OD Coder



- 92273 Full field electroretinogram for diabetes
- 92274 Multifocal electroretinogram
- \$118.32
- Written order, Interpretation and report
- Any diabetic retinopathy code
- Changes in retinal vascular appearance H35.011-013
- Hypertensive retinopathy H35.031-033
- Retinal ischemia H35.82

30

Diagnosis

- Still moderate non-proliferative
- But dangerously close to the 23.5 threshold
- If ERG DR score is greater than 23.5 then **34%** chance of needing ocular intervention
- If less than 23.5 then **3%** chance of needing ocular intervention

31

Management

- 1 Discuss with PCP
- 2 Start walking program
- 3 Begin omega-3 supplements
- 4 Discuss mediterranean diet
- 5 Recommend more aggressive HTN and cholesterol management

32

The Issue of Supplementation



I AM AN EVIDENCE-BASED CLINICIAN



I WILL CITE ONLY THE HIGHEST-QUALITY SOURCES



I HAVE NO SUPPLEMENTATION CONFLICTS OF INTEREST



THERE ARE MANY COMPANIES MAKING UNSUBSTANTIATED CLAIMS

33

2 diabetes supplements

- 1) Noretin (PRN)
 - o In this study, at 24 months, the difference between groups in the decrease of central subfield macular thickness was significant in favor of the DHA supplementation group and gains of >5 and >10 letters were significantly higher in the DHA supplementation group as compared with controls.
 - Lafuente, Maria, et al. "COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCSAHETERPENOIC ACID AND ANTI-OXIDANTS FOR DIABETIC MACULAR EDEMA." *Retina*, vol. 37, no. 7, July 2017, pp. 1277-1285.
- 2) DVS Formula (EyePromise)
 - o Participants in the DVS group showed a statistically significant improvement in visual acuity compared to the placebo group, a reduction in retinal thickness indicating a decrease in macular edema and the progression of diabetic retinopathy was significantly slower in the DVS group compared to the placebo group.
 - Chiquijo, Andrew SP, Gertman ID, Kowaluru RA. The Diabetes Visual Function Supplement Study (DVS). *Br J Ophthalmol*. 2016 Feb;100(2):227-34. doi: 10.1136/bjophthalmol-2014-306534. Epub 2015 Jun 18. PMID: 26088210; PMCID: PMC4752638.



34

Case

- 63 Y/O W/M, reports little to no exercise
- HA1C 8.1
- On Toujeo (insulin)
- Recently started taking Ozempic, Jardiance
- ODx: moderate NPDR, Hypertensive retinopathy, Chronic Angle closure glaucoma – mild, YAG PI 2020 OU, SLT 2020 OU
- IOP 21.2mmHg OD and 23.3 mmHg OS

35

Are you asking about HA1C?


Is there a better metric?



36




37



38




39



40



41



42

OD Coder  




- **Fundus Photography 92250**
 - \$35.98
 - Written order and interpretation
 - Bilateral
 - Unilateral RT or LT with 52 modifier (reduced services)
 - Not a substitute for a dilated exam
 - “if the study is performed as a screening, it is not covered by medicare”
 - Mutually exclusive with OCT nerve/macula – 59 modifier
 - **Now covered with E11.9**

Glare sensitivity H53.71
 Retinal ischemia H35.82
 Visual discomfort H53.143
 Visual distortions of shape and size H53.15

49

OD Coder Update



92137 OCT Angiography

- Jan 1
- Both traditional mac OCT 92134 and OCT-A 92137 must be performed and interpreted the same day
- Cannot be billed with 92133 or separately with 92134
- National Average
 - o 92134 \$31
 - o 92137 \$57
- Any codes that are reimbursable with 92134
- No glaucoma codes

50

OD Coder  



- **92273 Full field electroretinogram for diabetes**
- **92274 Multifocal electroretinogram**
- \$118.32
- Written order, Interpretation and report
- Any diabetic retinopathy code
- Changes in retinal vascular appearance H35.011-013
- Hypertensive retinopathy H35.031-033
- Retinal ischemia H35.82

51


Macular Thickness in DR

300-400 microns?

Over 400 microns – automatic referral


52

Examples




53

Which is worse for diabetic retinopathy, blood glucose levels that are too high or too low?



54

Blood sugar limbo may exacerbate retinopathy



“Our results show that these periodic low glucose levels cause an increase in certain retinal cell proteins, resulting in an overgrowth of blood vessels and worsening diabetic eye disease,”

Akret Sothi, MD, PhD; Chanyra Guo; Monika Dechavand; Yuezhi Ni; Sha Kachwal; Haley Magarity; Taylor Neus; Sabaiah Balagopal; Parthivraj; Michael Ramirez; Jaron Sanchez; Neeley Inamdar; Thomas W. Johnson; Miguel Flores-Belver; Maria Valeria Carro-Soler; Silvia Montanari. HIF-1a accumulation in response to transient hypoglycemia may worsen diabetic eye disease. Cell Reports. Published January 2023. DOI: <https://doi.org/10.1016/j.celrep.2022.111919>.

55

What about GLP-1's?

Glucagon-like peptide

- Hormone released when food is eaten to slow gastric emptying
- Increases insulin release
- Controls the feeling of satiety after eating

Options

- Trulicity
- Ozempic
- Rybelsis
- Mounjaro


56



57

In the Management of Diabetic Retinopathy

- When is the right time to refer to retina?
 - Advanced diagnostics like OCT-A and ERG can help



58

Physical activity = lower risk of Diabetic Retinopathy

- In Type 1
 - Along with lipid levels
- In Type 2
 - Impact is more pronounced in **vision threatening DR**
 - Improves lipid profile, BMI and blood pressure



Ren C, Liu M, U J, Gao Y, Xu J, Li J, Li P. Physical activity and risk of diabetic retinopathy: a systematic review and meta-analysis. Acta diabetologica. 2019 Aug 1;56:923-37.

59

Diabetic Retinopathy Exercise Tips

- Prioritize blood sugar control
 - Monitor levels, increase gradually to reduce BS dips
- Proper footwear
 - Peripheral neuropathy issues – custom fitting
- Cardio and Strength training
 - Yoga and Tai Chi
- Use caution within 1 week of intravitreal injections
 - Slightly increased risk of vitreous hemorrhage, endophthalmitis



60

Case

- 80 Y/O W/F
- Dx with AMD 2013
- Used AREDS/AREDS2 "off and on"
- 6 months ago Adapt Dx Rod Intercept 13.2

61

Optomaps

62

And now...

- 6 months ago, began new supplement, reports excellent compliance
- Begins a consistent walking program
- Adapt Dx 12.1 (Baseline 13.2)

63

Cross Line Comparison Report

64

65

2 AMD supplements prior to Intermediate Stage



Numacula Omega (PRN)

The AREDS 30 study supports Numaqua omega 3 by showing a **30% reduced risk of developing both CGA and wet form AMD over the 12-year study.**

SanGiovanni, John Paul, et al. "ω-3 Long-Chain Polyunsaturated Fatty Acid Intake and 12-Year Incidence of Neovascular Age-Related Macular Degeneration and Central Geographic Atrophy: AREDS Report 30, a Prospective Cohort Study from the Age-Related Eye Disease Study." *The American Journal of Clinical Nutrition*, vol. 90, no. 6, 7 Oct. 2009, pp. 1601-1607.



Macuhealth

Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in **significant increases in macular pigment and improvements in contrast sensitivity, glare disability, and photostress recovery.**

Alkufi, Yasirwan, et al. "Relationship between macular pigment and visual function in subjects with early age-related macular degeneration." *British Journal of Ophthalmology* 93, 2 (2009): 190-197.

66


OD Coder  

- **Computer ophthalmic imaging posterior segment 92134**
- \$37.80
- Written order and report
- Bilateral
 - Unilateral RT or LT with 52 modifier (reduced services)
- Once every 2 months
- Pathologies
 - Hundreds
 - Visual distortion of shape and size* H53.15
 - Scotomas and visual field defects H53.411-483
 - Retinal ischemia H35.82
 - Degenerative myopia H44.2E1-2E3
 - Other long-term drug treatment Z79.899 (baseline and annually)
- Mutually exclusive with 92250**




67

AMD Staging



Mild AMD characterized by medium-sized drusen (63µm to 125µm)



Intermediate AMD demonstrating large-sized drusen (>125µm)

- **Category 1:** Early AMD characterized by fewer than five small drusen, each below 63µm in size.
- **Category 2:** Mild AMD defined as multiple small drusen, a single intermediate-sized drusen from 63µm to 124µm or RPE changes.
- **Category 3:** Moderate AMD characterized by one large drusen greater than 125µm, extensive intermediate drusen or GA non-centrally.
- **Category 4:** Advanced AMD defined as more than one large drusen or GA centrally.

Age-Related Eye Disease Study Research Group. The AREDS system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001;132(5):668-81.

68


Case

- 88 Y/O W/M
- Here for AMD exam, last visit 1 year ago
- OcHx: Mild nonexudative AMD, hypertensive retinopathy, macular pucker OD
- Not taking his supplements (macuhealth), reports little to no exercise

69

Retina Map Change Analysis


Full Retina Thickness Map



Date: 05/10/2023, SSI=62.4

Date: 06/10/2024, SSI=63.7

70



71

Reclassify?

- Intermediate AMD
 - ARED2
 - Omega-3?
 - Exercise?

72

Type 1 "Occult" CNV

- New vessels develop in the choroid
- New vessels located **BELOW RPE** and **ABOVE** Bruch's membrane

73

Type 2 "Classic" CNV

- New vessels develop in choroid
- New vessels located **ABOVE** the RPE and **ABOVE** Bruch's membrane

74

Case

72 Y/O W/M

"VISION IN THE LEFT EYE IS NOT AS BRIGHT AS THE RIGHT EYE"

BCVA 20/25 OD AND 20/30 OS

PREVIOUS EXAM 9 MONTHS AGO – DX WITH MILD DRY AMD OU

75


Fundus Photos

76


77

OS OCT Cross Section

78



79



80

Diagnosis? SRNV

 Type 1 or Type 2?

Type 2

 Send to retina for anti-VEGF treatment

Avastin


81

Angio Retina QuickVue

Scan Quality 91%

ETDRS Non-Exudative

OCTA Visualizes Nonexudative CNV at High Risk for Exudation




82




83



84



85




86

Case

- 67 Y/O W/M
- Here for comprehensive exam complaining of occasional floaters
- BP 130/91 RAS, "white coat syndrome"
- Low risk glaucoma suspect based on large cupping

87



88




89


Diagnosis

- Hypertensive Retinopathy
 - Performed same day OCT-A
- Plan
 - Return for OCT-A and ERG

90



91



92

Hypertensive Retinopathy


- Signs
 - constricted and tortuous arterioles
 - retinal hemorrhage
 - hard exudates
 - cotton wool spots
 - Nerve edema
 - widening of the arteriole reflex
 - arteriovenous crossing signs
 - copper or silver wire arterioles

93

See the signs

- Salus sign – deflection of the vein
- Gunn's sign – tapering of vein at the crossing
- Bonnet's sign – banking of the distal vein to the crossing


94



95



96



97

Underdiagnosis of Hypertensive Retinopathy

- **Low Sensitivity of Detection Methods**
 - Sensitivity of detecting HR ranged from **3% to 21%**
 - Indicating that many cases may go unnoticed
 - van den Born BJ, Hulsman CA, Hoeksra JR, Schlingemann RJ, van Meurs GA. Value of routine funduscopy in patients with hypertension: systematic review. *BMJ*. 2005 Jul 9;331(7508):73.
- **High Prevalence Yet Limited Recognition**
 - **44%** of referred hypertensive patients **had undiagnosed HR**
 - including HR in the assessment of end-organ damage increased the number of patients requiring treatment from **3% to 14%**
 - HR is often overlooked in treatment decisions
 - Kollman SA, van Sijl AM, van der Sluis FA, van de Ree MA. Consideration of hypertensive retinopathy as an important end-organ damage in patients with hypertension. *J Hum Hypertens*. 2017 Feb;31(2):121-125.
- **Diagnostic Challenges and Variability**
 - High interobserver (**20% to 40%**) and intraobserver (**10% to 33%**) variability
 - Schmieler RE. Hypertensive retinopathy: a window to vascular remodeling in arterial hypertension. *Hypertension*. 2009 Jan 1;51(1):43-4.

98

Summary

- Your patients are counting on us to help manage the 3 most common retinal diseases
- Improving and refining management protocol leads to better patient care
- Our patients deserve it

99

Thank You!!!

mcybor@nittanyeye.com

MIKECYMBOR.COM

100